Roberto Costillas Perez: Vaginal Microbiota’s Role in Assisted Reproduction Outcomes
Roberto Costillas Perez, Founder and CEO at Fertypharm, shared a post on LinkedIn:
“Vaginal Microbiota and Outcomes in Assisted Reproduction (Summary)
A Lactobacillus-dominated vaginal microbiota, especially L. crispatus, favors an acidic and protective environment, associated with better outcomes in assisted reproduction.
Vaginal dysbiosis (elevated pH, predominance of anaerobes like Gardnerella, Prevotella or Atopobium) correlates with lower implantation rates, higher miscarriage and worse overall prognosis.
Impact on Reproductive Outcomes
Lactobacillus-dominated Microbiota
- Implantation Rate: 40–60%
- Clinical Pregnancy: 45–65%
- Spontaneous Miscarriage: 10–20%
- Live Birth: 35–55% per transfer
Vaginal Dysbiosis
- Implantation: reduction of ~30–40%
- Clinical Pregnancy: 20–35%
- Miscarriage: 20–30%
- Live Birth: 15–30% per transfer
Clinical Management
1. Accessible Basic Screening
- A simple vaginal pH strip is a quick and useful method:
- pH > 4.5 → suggests dysbiosis or bacterial vaginosis.
- It allows identifying patients who could benefit from a more detailed assessment in assisted reproduction contexts.
2. When to Study Vaginal Microbiota
Indicated in:
- Repeated implantation failures
- Recurrent miscarriages
- Recurrent vaginosis or suspicion of clinically relevant dysbiosis
- Not recommended as routine screening for all patients.
3. Recommended Interventions
- Oral probiotics with lactobacilli
- They can be a good strategy to promote or restore a eubiotic environment before and during assisted reproduction cycles.
- Evidence particularly supports strains like L. rhamnosus and L. Plantarum and L. Crispatus.
- Antibiotic treatment only if documented dysbiosis exists (PCR, NGS or clinical with elevated pH and symptoms), avoiding indiscriminate empirical use.
- Re-evaluation (pH or specific tests) before embryo transfer in cases of prior dysbiosis.
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 28, 2026, 16:59Unlocking the Potential of Menstrual Blood in Health Testing – Global Women’s Health Innovation Conclave
-
Jan 28, 2026, 16:57New Insights on Oocyte Yield in Endometriosis and PCOM – RBMO
-
Jan 28, 2026, 16:51Transform Your Expertise with ESHRE eCampus Learning – ESHRE
-
Jan 28, 2026, 16:46Accelerate Your Growth at the AP3G National Meeting – ASRM
-
Jan 28, 2026, 16:43Debojit Saha: Unraveling Chromosomal Errors in Aging Human Eggs
-
Jan 28, 2026, 16:38Silvia Vannuccini: RBMO Highlights Key Insights on Adenomyosis Awareness
-
Jan 28, 2026, 16:32Maximilian Attwood: Challenging Medical Misogyny in Endometriosis Research
-
Jan 28, 2026, 16:29Ioakeim Sapantzoglou: New Perspectives on Fetal Growth Restriction and Genetic Testing
-
Jan 28, 2026, 16:26Enhancing Pre-Eclampsia Prediction with Doppler Indices – ISUOG
